期刊
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
卷 16, 期 1, 页码 11-20出版社
HARBORSIDE PRESS
DOI: 10.6004/jnccn.2018.0002
关键词
-
类别
资金
- Abbott Laboratories
- Amgen Inc.
- Celgene Corporation
- Janssen Pharmaceutica Products, LP
- Novartis Pharmaceuticals Corporation
- sanofiaventis U.S.
- Takeda Pharmaceuticals North America, Inc.
- Kesios Therapeutics
- NOXXON Pharma AG
- SkylineDx
- Prothena Corporation
- Pfizer, Inc.
- Amgen, Inc.
- BlueBirdbio
- Gilead Sciences, Inc.
- Genetech, Inc.
- Roche Laboratories, Inc.
- sanofi-aventis U.S.
- Genzyme Corporation
The NCCN Guidelines for Multiple Myeloma provide recommendations for diagnosis, evaluation, treatment, including supportive-care, and follow-up for patients with myeloma. These NCCN Guidelines Insights highlight the important updates/changes specific to the myeloma therapy options in the 2018 version of the NCCN Guidelines.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据
分享论文
